Table 3 CXCR4 and CCR5 expression in CD4+ T lymphocytes
From: In vivo effect of statins on the expression of the HIV co-receptors CCR5 and CXCR4
Parameter | Time of treatment | Placebo group (n = 43) | Lovastatin group (n = 41) |
|---|---|---|---|
(95% CI) | (95% CI) | ||
% CD4+/CXCR4+ T cells | Baseline | 68.5 (48.2 - 90.2) | 58.5 (32.0 - 87.1) |
6Â months post | 60.0 (41.0 - 82.0) | 66.4 (43.2 - 90.0) | |
12Â months post | 58.5 (33.4 - 87.5) | 66.0 (40.1 - 87.0) | |
* EAC by treatment | 1.1% (−6.3 to 8.5) | ||
MFI CXCR4 in CD4+/CXCR4+ T cells | Baseline | 157.4 (63.6 - 221.0) | 118.7 (76.0 - 176.4) |
6Â months post | 132.9 (44.4 - 195.6) | 117.0 (72.1 - 200.7) | |
12Â months post | 132.1 (35.3 - 231.4) | 116.1 (39.3 - 184.6) | |
EAC by treatment | −39.2 (−91.1 to 13.4) | ||
% CD4+/CCR5+ T cells | Baseline | 17.8 (11.6 - 34.7) | 23.6 (12.0 - 64.7) |
6Â months post | 19.2 (10.5 - 28.3) | 26.0 (13.9 - 57.3) | |
12Â months post | 21.5 (9.8 - 60.0) | 22.5 (10.5 - 46.0) | |
EAC by treatment | 2.84% (−4.1 to 9.9) | ||
MFI CCR5 in CD4+/CCR5+ T cells | Baseline | 67.9 (50.0 - 94.9) | 71.6 (54.1 - 90.6) |
6Â months post | 63.0 (42.7 - 99.0) | 66.2 (44.0 - 98.7) | |
12Â months post | 58.4 (33.5 - 107.3) | 83.5 (42.1 - 125.5) | |
EAC by treatment | −5.7 (−23.9 to 12.4) | ||